NASDAQ · Financial Statements

Xilio Therapeutics, Inc. (XLO) Financial Statements

$7.57 NASDAQ: XLO Market Cap $49.81M

Xilio Therapeutics, Inc. most recently reported annual revenue of $44.0M, a net loss of $35.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Xilio Therapeutics, Inc.: net profit was positive in 0 of 7 reported years; operating margin moved from -955.0% to -95.9%, a shift of +859.0 percentage points; the most recent year shows a net loss of $35.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$0$0$0$0$0$6.0M$44.0M
Operating Expenses$19.0M$55.0M$75.0M$89.0M$79.0M$67.0M$86.0M
Operating Profit$-19.0M$-55.0M$-75.0M$-89.0M$-79.0M$-61.0M$-42.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%-955.0%-95.9%
Other Income$2.0M$-1.0M$-1.0M$1.0M$3.0M$2.0M$7.0M
Interest$0$1.0M$1.0M$0$0$0$0
Depreciation$0$1.0M$1.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax$-17.0M$-55.0M$-76.0M$-88.0M$-76.0M$-58.0M$-35.0M
Tax$0$0$0$0$0$0$0
Net Profit$-17.0M$-55.0M$-76.0M$-88.0M$-76.0M$-58.0M$-35.0M
EPS$-592.06$-1475.88$-189.28$-45.08$-38.92$-15.26$-4.19
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$2.0M$2.0M$2.0M$3.0M$8.0M$19.0M$14.0M$13.0M$19.0M
Operating Expenses$17.0M$18.0M$17.0M$17.0M$17.0M$15.0M$17.0M$22.0M$21.0M$26.0M$27.0M$22.0M
Operating Profit$-17.0M$-18.0M$-17.0M$-15.0M$-15.0M$-14.0M$-14.0M$-14.0M$-2.0M$-12.0M$-14.0M$-3.0M
Operating Margin0.0%0.0%0.0%-623.8%-652.3%-790.5%-472.7%-177.7%-10.1%-86.5%-111.6%-18.7%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-17.0M$-18.0M$-17.0M$-14.0M$-14.0M$-13.0M$-13.0M$-16.0M$-16.0M$10.0M$-10.0M$-6.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-17.0M$-18.0M$-17.0M$-14.0M$-14.0M$-13.0M$-13.0M$-16.0M$-16.0M$10.0M$-10.0M$-6.0M
EPS$-8.54$-8.96$-8.68$-4.48$-3.08$-2.80$-2.52$-4.34$-1.54$0.81$-0.58$-0.33

Over the 7 years reported for Xilio Therapeutics, Inc., borrowings decreased from $19.0M in 2019 to $7.0M in 2025, cash stood at $138.0M in the latest year, shareholders' equity was $37.0M, current assets covered current liabilities 2.59 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$63.0M$36.0M$222.0M$139.0M$61.0M$71.0M$155.0M
Current Assets$51.0M$21.0M$203.0M$124.0M$48.0M$60.0M$145.0M
Cash$49.0M$19.0M$198.0M$120.0M$45.0M$55.0M$138.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$5.0M
Fixed Assets$10.0M$14.0M$14.0M$13.0M$11.0M$9.0M$8.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$0$2.0M$2.0M$0$2.0M$2.0M
Other Assets$0$0$0$0$0$0$0
Total Liabilities$24.0M$42.0M$36.0M$34.0M$24.0M$53.0M$119.0M
Current Liabilities$5.0M$22.0M$13.0M$21.0M$16.0M$27.0M$56.0M
Borrowings$19.0M$22.0M$21.0M$20.0M$13.0M$8.0M$7.0M
Other Liabilities$6.0M$20.0M$15.0M$14.0M$12.0M$45.0M$112.0M
Equity$0$0$0$0$0$0$37.0M
Reserves$39.0M$-5.0M$185.0M$106.0M$37.0M$18.0M$35.0M

For Xilio Therapeutics, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $6.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow$-18.0M$-36.0M$-81.0M$-76.0M$-69.0M$-18.0M$-5.0M
Investing Cash Flow$-1.0M$-4.0M$-2.0M$-4.0M$-1.0M$0$-1.0M
Financing Cash Flow$-10.0M$0$0$0$0$26.0M$0
Net Cash Flow$41.0M$-28.0M$179.0M$-78.0M$-76.0M$11.0M$82.0M
Free Cash Flow$-19.0M$-38.0M$-82.0M$-78.0M$-69.0M$-18.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA3.44
FCF Yield-103.42%
Quick Ratio4.25
Interest Coverage—
Return 1Y-9.64%
Return 3Y-75.69%
Return 5Y—

Xilio Therapeutics, Inc. (XLO) financials — frequently asked questions

What is Xilio Therapeutics, Inc.'s annual revenue?

Xilio Therapeutics, Inc. (XLO) reported annual revenue of $44.0M in its most recent fiscal year.

What is Xilio Therapeutics, Inc.'s net profit?

Xilio Therapeutics, Inc. (XLO) reported a net loss of $35.0M in its most recent fiscal year.

What is XLO EV/EBITDA?

Xilio Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 3.44.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
XLO Overview XLO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.